[go: up one dir, main page]

AR061728A1 - COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1 - Google Patents

COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1

Info

Publication number
AR061728A1
AR061728A1 ARP070102894A ARP070102894A AR061728A1 AR 061728 A1 AR061728 A1 AR 061728A1 AR P070102894 A ARP070102894 A AR P070102894A AR P070102894 A ARP070102894 A AR P070102894A AR 061728 A1 AR061728 A1 AR 061728A1
Authority
AR
Argentina
Prior art keywords
delta
composition
alpha
ligand
alfa
Prior art date
Application number
ARP070102894A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR061728A1 publication Critical patent/AR061728A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion para tratar un trastorno o afeccion usando un ligando alfa-2-delta, como por ejemplo, ácido (3S,4R,5R)-3-amino-4,5-dimetil octanoico, con gran afinidad y selectividad para el subtipo de la subunidad alfa-2-delta-1del canal de calcio. La administracion del ligando selectivo alfa-2-delta-1, o una sal farmacéuticamente aceptable, a un mamífero, incluyendo un hombre, evita o reduce los efectos adversos en comparacion con la administracion de un ligando no selectivo alfa-2-delta. Reivindicacion 7: La composicion de acuerdo con la reivindicacion 1 caracterizada porque el trastorno o afeccion es seleccionado de dolor, fibromialgia, epilepsia, síndrome de piernas inquietas, sofocos, trastornos del humor y trastornos del sueno.A composition for treating a disorder or condition using an alpha-2-delta ligand, such as, for example, (3S, 4R, 5R) -3-amino-4,5-dimethyl octanoic acid, with high affinity and selectivity for the subtype of the alpha-2-delta-1 subunit of the calcium channel. The administration of the selective alpha-2-delta-1 ligand, or a pharmaceutically acceptable salt, to a mammal, including a man, avoids or reduces adverse effects compared to the administration of a non-selective alpha-2-delta ligand. Claim 7: The composition according to claim 1 characterized in that the disorder or condition is selected from pain, fibromyalgia, epilepsy, restless legs syndrome, hot flashes, mood disorders and sleep disorders.

ARP070102894A 2006-06-30 2007-06-28 COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1 AR061728A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81815406P 2006-06-30 2006-06-30

Publications (1)

Publication Number Publication Date
AR061728A1 true AR061728A1 (en) 2008-09-17

Family

ID=38739992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102894A AR061728A1 (en) 2006-06-30 2007-06-28 COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1

Country Status (4)

Country Link
JP (1) JP2008013555A (en)
AR (1) AR061728A1 (en)
TW (1) TW200819123A (en)
WO (1) WO2008004067A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160403A (en) 2007-11-05 2017-03-15 Unilever Plc Process for manufacturing tea products
AU2018274569B2 (en) * 2017-05-26 2022-06-30 Novassay Sa Voltage-Gated Calcium Channel auxilliary subunit alpha 2 delta and uses thereof
WO2021079887A1 (en) * 2019-10-25 2021-04-29 国立大学法人京都大学 Preventative or therapeutic agent for tauopathy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260850T3 (en) * 1997-10-27 2006-11-01 Warner-Lambert Company Llc CYCLINE AMINOACIDS AND ITS DERIVATIVES USED AS PHARMACEUTICAL AGENTS.
AU765802B2 (en) * 1997-12-16 2003-10-02 Warner-Lambert Company 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EA004398B1 (en) * 1999-06-10 2004-04-29 Уорнер-Ламберт Компани Mono- and disubstituted 3-propyl gamma-aminobutyric acids
HN2000000224A (en) * 1999-10-20 2001-04-11 Warner Lambert Co BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS
WO2002085839A1 (en) * 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
NI200300043A (en) * 2002-03-28 2003-11-05 Warner Lambert Co AMINO ACIDS WITH AFFINITY FOR THE PROTEIN a2DELTA.
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
EP1667957A2 (en) * 2003-09-25 2006-06-14 Warner-Lambert Company LLC Amino acids with affinity for the alpha2delta-protein
WO2005102390A2 (en) * 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
EP1774318A2 (en) * 2004-07-13 2007-04-18 The Regents of The University of California Models and methods for nociception, pain transduction, and screening for analgesic compounds
WO2006100606A2 (en) * 2005-03-24 2006-09-28 Warner-Lambert Company Llc Preparation of beta-amino acid precursors via indium (iii) mediated markovnikov addition and knoevenagel condensation

Also Published As

Publication number Publication date
TW200819123A (en) 2008-05-01
JP2008013555A (en) 2008-01-24
WO2008004067A3 (en) 2009-01-29
WO2008004067A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
EA201100896A1 (en) COMPOSITION INTENDED FOR SUCKING NICOTINE FROM THE FATAL CAVITY WITH THE PURPOSE TO STOP SMOKING
EA200970435A1 (en) TREATMENT OF GENERAL DEVELOPMENT DISORDERS
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
UY30686A1 (en) "NICOTINIC ACETILCOLINE RECEPTOR, SELECTIVE SUBTIPE OF AMIDAS DE DIAZABICILOALCANOS"
DK1970059T3 (en) Calcium dobesilate drug for the treatment and prophylaxis of tendon disorders
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
EA201170018A1 (en) Razagilin to change the flow of Parkinson's disease
EA200802412A1 (en) THERAPEUTIC COMBINATIONS FOR SUPPORTING MEDICAL CONDITIONS
UA107103C2 (en) NICOTINATED SOFT GELATINE PASTILES
MY199903A (en) Combination therapy with controlled-release cnp agonists
AR070025A1 (en) USE OF DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF COCLEAR TINNITUS AND PHARMACEUTICAL COMPOSITION
MX2009010450A (en) The use of pde7 inhibitors for the treatment of movement disorders.
MX339555B (en) USE OF PHOSPHODESTERASE 7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS.
IL307992A (en) Isoxazoline parasiticide formulations and methodsfor treating blepharitis
MX2021005967A (en) Purified forms of rofecoxib, methods of manufacture and use.
EA202091446A1 (en) METHODS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES
RU2015109566A (en) NEW EXTRACTS FROM CYNARA SCOLYMUS, COFFEA spp. AND OLEA EUROPAEA FOR THE TREATMENT OF A METABOLIC SYNDROME
MY151230A (en) Novel method
MX2021007142A (en) Organic compounds.
AR061728A1 (en) COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1
EA200970127A1 (en) MODULATOR OF GLUCOCORTICOSTEROID RECEPTORS AND METHODS OF ITS APPLICATION
CO6400019A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES RACETAM AND CARNITINE AND PROCESS FOR PREPARATION
BR112015012497A2 (en) pharmaceutical combinations
RU2013154071A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF HEAD-WAYS
EA201170583A1 (en) NEW COMPOSITION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTEMIA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal